NasdaqCM - Nasdaq Real Time Price USD

Coeptis Therapeutics Holdings, Inc. (COEPW)

0.0179

+0.0034

+(23.45%)

As of 12:13:10 PM EDT. Market Open.

Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline

• COEP forms GEAR Therapeutics, as a majority-owned subsidiary, to advance GEAR-modified natural killer (NK) cells into first-in-human studies for broad range of cancers and other therapeutic modalities. WEXFORD, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) ("the Company" or "Coeptis"), a pioneering technology firm at the forefront of innovative biotechnology solutions today announced it has successfully licensed exclusive worldwide development and commercialization right

GlobeNewswire last month

COEP
+2.76%
COEPW
+23.45%
COEPTIS’ NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan

Leveraging Advanced AI and Robotics to Revolutionize Marketing Strategies in Defense and Security SectorsWEXFORD, Pa., March 07, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) ("the Company" or "COEPTIS"), a pioneering technology firm at the forefront of innovative biotechnology solutions today announced its strategic partnership with COEPTIS’ NexGenAI Affiliates Network “NexGen” and NUBURU, Inc. “NUBURU” (NYSE: BURU), a leading innovator in high-power blue laser technology. This collabor

GlobeNewswire last month

COEP
+2.76%
COEPW
+23.45%
BURU
COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing

This partnership gives COEPTIS access to AI-driven campaign management, predictive analytics, and automated outreach capabilities with MarketLeverage’s 5,500 advertisers and 55,000 publishers, creating one of the most expansive and effective affiliate networks in the industryWEXFORD, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) ("the Company" or "Coeptis"), a pioneering technology firm at the forefront of innovative biotechnology solutions, is thrilled to announce a partne

GlobeNewswire 2 months ago

COEP
+2.76%
COEPW
+23.45%
Coeptis Therapeutics (COEP): Launching AI-Focused Venture Arm to Fuel Innovation

We recently published a list of Top 10 Must-See AI News And Ratings For Investors. In this article, we are going to take a look at where Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) stands against other top must-see AI news and ratings for investors. A high US inflation print has diminished hopes of interest rate cuts […]

Insider Monkey 2 months ago

COEPW
+23.45%
COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups

WEXFORD, Pa., Feb. 13, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a pioneering technology company dedicated to advancing cutting-edge technologies and artificial intelligence at the forefront of innovative biotechnology therapeutic solutions, today announced the launch of COEP Venture Group, a newly established investment arm dedicated to funding and accelerating technology startups specializing in Artificial Intelligence (AI), Robotic Process Automation

GlobeNewswire 2 months ago

COEP
+2.76%
COEPW
+23.45%
Coeptis Therapeutics Holdings, Inc. (COEP) Raises $10M to Advance AI-Driven Cell Therapy Innovations

We recently compiled a list of the 10 AI News Updates Making Waves on Wall Street. In this article, we are going to take a look at where Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) stands against the other AI stocks. The evolving space of AI has been a major focus these days, as experts and executives are […]

Insider Monkey 2 months ago

COEPW
+23.45%
COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration

COEPTIS, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a pioneering technology company dedicated to advancing cutting-edge technologies and artificial intelligence at the forefront of innovative biotechnology therapeutic solutions, today announced the successful closure of an additional $5.7 million in its final Series A Preferred Offering, bringing the total financing round to $10 million. This significant achievement highlights investor confidence in Coeptis' innovative therapeutic solutio

PR Newswire 2 months ago

COEP
+2.76%
COEPW
+23.45%
Coeptis Therapeutics Holdings, Inc. (COEP): Pioneering AI-Powered Marketing for Healthcare Innovation

We recently published a list of 10 AI News and Ratings Investors Should Take a Look At. In this article, we are going to take a look at where Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) stands against other AI news and ratings investors should take a look at. As AI continues to reshape industries, investors are […]

Insider Monkey 2 months ago

COEPW
+23.45%
Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, is excited to announce its rebranding to COEPTIS, marking a transformative shift in its business strategy. This pivotal change reflects our commitment to expanding beyond biopharmaceuticals and embracing diverse growth opportunities in technology-driven sectors.With the establishment of our new T

PR Newswire 2 months ago

COEP
+2.76%
COEPW
+23.45%
Coeptis Therapeutics Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, is excited to announce the expansion of its technological initiatives to include cutting-edge artificial intelligence and innovative blockchain solutions.

PR Newswire 2 months ago

COEP
+2.76%
COEPW
+23.45%
Coeptis Therapeutics Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced it has regained compliance with Listing Rule 5550(a)(2) (the "Bid Price Rule"), as required by the Nasdaq Hearings Panel's decision of September 17, 2024.

PR Newswire 2 months ago

COEP
+2.76%
COEPW
+23.45%
Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, is excited to announce the initial rollout of its recently introduced NexGenAI Affiliates Network platform. With five new customers already signed on to leverage the platform's cutting-edge AI-driven marketing solutions, Coeptis believes it can bolster its operational landscape and amplify revenu

PR Newswire 3 months ago

COEP
+2.76%
COEPW
+23.45%
Why Is Coeptis Therapeutics Stock Falling On Friday?

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) shares are trading lower on Friday. The firm announced plans to implement a 1-for-20 reverse stock split, which will take effect on December 31. The decision follows authorization from the company's board of directors and majority stockholders. The reverse stock split aims to help the company meet the Nasdaq Capital Market's minimum bid price requirement of $1.00 per share, which is necessary to maintain its listing on the exchange. Also Read: 3

Benzinga 3 months ago

COEPW
+23.45%
^RUT
Coeptis Therapeutics Announces Reverse Stock Split

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced it will proceed with a 1-for-20 reverse stock split (the "Reverse Split") of its issued and outstanding shares of common stock, par value $0.0001, following authorization by its board of directors (the "Board") and majority stockholders to effect a reverse stock split by a ratio o

PR Newswire 3 months ago

COEP
+2.76%
COEPW
+23.45%
Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company specializing in innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, proudly announces the completion of its acquisition of the NexGenAI Affiliates Network platform alongside the official launch of Coeptis Technologies. This new division is strategically aimed at diversifying the company's growth potential.

PR Newswire 3 months ago

COEP
+2.76%
COEPW
+23.45%
Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, is excited to announce the official launch of Coeptis Technologies, a new division aimed at diversifying and enhancing the company's growth potential. This strategic move underscores Coeptis' commitment to maximizing shareholder value and capitalizing on high-growth opportunities across different

PR Newswire 4 months ago

COEP
+2.76%
COEPW
+23.45%
Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, is pleased to announce the execution of a Binding Letter of Intent for the acquisition of NexGenAI Affiliates Network, a platform developed by NexGenAI Solutions Group and its affiliates ("NexGenAI") that offers AI-powered marketing software and robotic process automation ("RPA") capabilities. By

PR Newswire 4 months ago

COEP
+2.76%
COEPW
+23.45%
Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced that results from their Phase 1 study evaluating DVX201, an allogeneic natural killer (NK) cell therapy, for the treatment of patients hospitalized with COVID-19 has been accepted for publication in Molecular Therapy Methods and Clinical Development.

PR Newswire 5 months ago

COEP
+2.76%
COEPW
+23.45%
Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced the expansion of its license agreement with Deverra Therapeutics Inc. ("Deverra"), broadening the potential applications of its allogeneic natural killer (NK) cell technology. This expansion includes the use of unmodified NK cells in treating viral infections, pandemic-related ill

PR Newswire 5 months ago

COEP
+2.76%
COEPW
+23.45%
Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, announced that its Chief Scientific and Medical Officer Colleen Delaney, MD will attend and present at the following upcoming fall conferences. These events, including the 2024 AABB Annual Meeting, the 50th ASHI Annual Meeting, the Advanced Therapies USA Congress, and the Donor Selection & Cell S

PR Newswire 6 months ago

COEP
+2.76%
COEPW
+23.45%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Coeptis Therapeutics Holdings, Inc. (COEPW)

Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline

COEPTIS’ NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan

COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing

Coeptis Therapeutics (COEP): Launching AI-Focused Venture Arm to Fuel Innovation

COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups

Coeptis Therapeutics Holdings, Inc. (COEP) Raises $10M to Advance AI-Driven Cell Therapy Innovations

COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration

Coeptis Therapeutics Holdings, Inc. (COEP): Pioneering AI-Powered Marketing for Healthcare Innovation

Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation

Coeptis Therapeutics Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation

Coeptis Therapeutics Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform

Why Is Coeptis Therapeutics Stock Falling On Friday?

Coeptis Therapeutics Announces Reverse Stock Split

Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies

Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies

Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries

Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development

Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use

Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy